Autologous Blood Transfusions in the Czech Republic in 2001
Authors:
J. Masopust
Authors‘ workplace:
Transfuzní oddělení Masarykovy nemocnice, Ústí nad Labem
Published in:
Transfuze Hematol. dnes,, 2002, No. 3, p. 107-111.
Category:
Overview
Introduction:
Autologous blood transfusions remain despite the increasing safety and quality ofallogeneic transfusions an important part of haemotherapy. Methods: 151 departments were sentquestionnaires mapping the implementation of autologous programmes in the CR in 2001. Results: 101departments responded. 19318 preoperative autologous whole blood donations were made (4.5 % of allwhole blood donations, incl. allogeneic ones). This number included 100 donations in children and 7 inpregnant women. In 2001 182 autologous donations by erythrocytopheresis and 118 by plasmapheresis,2642 acute normovolaemic haemodilution (ANH) and 208 cases of perioperative blood salvage (PBS)were made. From collected autologous blood two thirds served production of whole blood, one thirdproduction of red blood cells and somewhat less plasma. Discussion and conclusion: Among autologoustransfusions preoperative autologous blood donation (PAD) dominates, although since 1999 the numberof PADhas been declining.MorePADwere implemented in the Moravian regions.Detection of anti-HCV,anti-HIV 1,2, HBsAg, and syphilis is higher in autologous blood donations than in alogeneic ones. Insubjects who donated for the first time the incidence ofHCVwas surprisingly higher than in autologousblood donors. The number of apheretic autologous donations declined as compared with previous year.Data on ANH and PBS are underrated due to the non-participation of many anaesthesiological andresuscitation departments incl. large hospitals.
Key words:
autologous blood transfusion, apheresis, acute normovolaemic haemodilution, perioperativeblood salvage, preoperative blood donation
Labels
Haematology Internal medicine Clinical oncologyArticle was published in
Transfusion and Haematology Today
2002 Issue 3
Most read in this issue
- Rituximab (Chimeric Anti-CD20 Monoclonal Antibody) in the Treatment of Non-Hodgkin’sLymphomas. Our Initial Experience
- Iron Overload and its Association with HaematologicalFindings in Porphyria Cutanea Tarda
- Survey of Public Opinion of Non-remunerated Blood Donors
- Preparation and Use of Tumor Antigen from Pathological Immunoglobulinfor Patients with Multiple Myeloma